DeMots H, Rahimtoola S H, Kremkau E L, Bennett W, Mahler D
J Clin Invest. 1976 Aug;58(2):312-9. doi: 10.1172/JCI108474.
The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man. We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure. Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted. Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients. Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed. The maximum velocity of contractile element shortening increased from 1.68+/-0.11 ml/s to 2.18+/-0.21 muscle-lengths/s (P less than 0.05) and is consistent with an increase in contractility. No significant change in these parameters occurred in the control patients. No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients. We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal. Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption. Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.
在存在阻塞性冠状动脉疾病的情况下,洋地黄糖苷对心肌供氧量和需氧量的影响尤为令人关注,但此前尚未在人体中进行测量。我们评估了哇巴因(0.015毫克/千克体重)对11例无临床充血性心力衰竭的严重慢性冠状动脉疾病患者的血流动力学、容积和代谢参数的影响。由于方案较长且涉及可能影响测定的干预措施,我们还对9例患者采用了相同的方案,但未给予哇巴因。给予哇巴因的每位患者左心室舒张末期压力和左心室舒张末期容积均下降了,尽管最初只有2例患者这些指标升高。在完成哇巴因输注1小时后,左心室舒张末期压力从11.5±1.4(均值±标准误)降至5.6±0.9毫米汞柱(P<0.001),左心室舒张末期容积从100±17降至82±12毫升/平方米(P<0.01)。收缩成分缩短的最大速度从1.68±0.11毫升/秒增加至2.18±0.21肌肉长度/秒(P<0.05),这与收缩力增加一致。对照患者这些参数无显著变化。给予哇巴因后心肌耗氧量无显著变化,但这可能与哇巴因组患者平均动脉压下降幅度大于对照组患者有关。我们得出结论,在无临床充血性心力衰竭的慢性冠状动脉疾病患者中,给予哇巴因后即使左心室舒张末期容积最初正常也会下降。尽管这种下降会伴随着壁张力降低,从而心肌耗氧量减少,但可能幅度不足以防止心肌耗氧量净增加。然而,代偿机制可防止静息心肌代谢恶化。